Fenwick represented Royalty Pharma on the deal.Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, announced the acquisition…
Royalty Pharma’s Interest Acquisition in Amgen’s Olpasiran
